Carregant...
Correction of bleeding in experimental severe hemophilia A by systemic delivery of factor VIII-encoding mRNA
The treatment or prevention of bleeding in patients with hemophilia A relies on replacement therapy with different factor VIII (FVIII)-containing products or on the use of by-passing agents, i.e., activated prothrombin complex concentrates or recombinant activated factor VII. Emerging approaches inc...
Guardat en:
| Publicat a: | Haematologica |
|---|---|
| Autors principals: | , , , , , , , , |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
Ferrata Storti Foundation
2020
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7109737/ https://ncbi.nlm.nih.gov/pubmed/31289204 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3324/haematol.2018.210583 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|